Navigation Links
AcelRx Announces Achievement of the Primary End-Point in Phase 3 Comparative Study Involving the Sufentanil NanoTab PCA System and Plans to Hold a Conference Call and Webcast Tomorrow to Discuss Top-Line Results
Date:11/14/2012

REDWOOD CITY, Calif., Nov. 14, 2012 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, announced today it had met the primary endpoint in the Phase 3 non-inferiority study of the sublingual Sufentanil NanoTab PCA System vs. IV PCA with morphine. The top-line data is expected to be released prior to market opening on November 15, 2012, and following such release AcelRx management will host an investment-community conference call at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time) to discuss the Phase 3 top-line results.

The conference call and webcast will be held tomorrow, Thursday, November 15, 2012 at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time) to discuss the Phase 3 top-line results. To listen to the conference call, dial in approximately ten minutes before the scheduled call to (800) 860-2442 for domestic callers, (866) 605-3852 for Canadian callers, or (412) 858-4600 for international callers. Those interested in listening to the conference call live via the Internet may do so by visiting the Investor Relations section of the company's website at www.acelrx.com.

A webcast replay will be available on the AcelRx website for 90 days following the call by visiting the Investor Relations section of the company's website at www.acelrx.com.

About AcelRx Pharmaceuticals, Inc.

AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain. AcelRx's lead product candidate, the ARX-01 Sufentanil NanoTab PCA System, is currently in Phase 3 clinical development and is designed to solve problems as
'/>"/>

SOURCE AcelRx Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. AcelRx Pharmaceuticals Reports First Quarter 2012 Financial Results
2. AcelRx Pharmaceuticals Announces Pricing of a $10.0 Million PIPE Financing
3. AcelRx Pharmaceuticals, Inc. to Webcast, Live, at RetailInvestorConferences.com on July 12th
4. AcelRx Pharmaceuticals, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
5. AcelRx Pharmaceuticals Receives Two Additional U.S. Patents for Small-Volume Oral Transmucosal Dosage Forms
6. AcelRx Pharmaceuticals to Hold Second Quarter 2012 Financial Results Conference Call and Webcast on August 9, 2012
7. AcelRx Pharmaceuticals to Present at the Canaccord Genuity 32nd Annual Healthcare Conference
8. AcelRx Pharmaceuticals Reports Second Quarter 2012 Financial Results
9. AcelRx Pharmaceuticals to Present at Three Upcoming Investor Conferences
10. AcelRx Pharmaceuticals Receives Fourth and Fifth U.S. Patents for Small-Volume Oral Transmucosal Dosage Forms
11. AcelRx Pharmaceuticals to Present at the UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... MOUNTAIN VIEW, Calif., July 31, 2014 IRIDEX Corporation ... the second quarter and six months ended June 28, 2014.  ... quarter of 2014, up 15% from $9.2 million in the ... the first quarter of 2014. Revenues for the first six ... million in the first six months of last year. ...
(Date:7/31/2014)... SAN DIEGO, July 31, 2014 Tandem Diabetes Care®, ... and manufacturer of the t:slim® Insulin Pump, today reported its ... In comparing the second quarter of 2014 to ... percent to $10.3 million from $5.5 million , t:slim ... pumps In comparing six months ended June 30, ...
(Date:7/31/2014)... 2014 Pharmacyclics, Inc. (the "Company") (Nasdaq: ... the quarter ended June 30, 2014. Financial Results ... Revenue Total revenue for the quarter ended June 30, ... quarter ended June 30, 2013 primarily due to IMBRUVICA ® ... Total revenue for the six months ended June 30, ...
Breaking Medicine Technology:IRIDEX Reports 2014 Second Quarter, Six-Month Results 2IRIDEX Reports 2014 Second Quarter, Six-Month Results 3IRIDEX Reports 2014 Second Quarter, Six-Month Results 4IRIDEX Reports 2014 Second Quarter, Six-Month Results 5IRIDEX Reports 2014 Second Quarter, Six-Month Results 6IRIDEX Reports 2014 Second Quarter, Six-Month Results 7Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 2Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 3Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 4Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 5Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 6Pharmacyclics Reports Second Quarter 2014 Results 2Pharmacyclics Reports Second Quarter 2014 Results 3Pharmacyclics Reports Second Quarter 2014 Results 4Pharmacyclics Reports Second Quarter 2014 Results 5Pharmacyclics Reports Second Quarter 2014 Results 6Pharmacyclics Reports Second Quarter 2014 Results 7Pharmacyclics Reports Second Quarter 2014 Results 8Pharmacyclics Reports Second Quarter 2014 Results 9Pharmacyclics Reports Second Quarter 2014 Results 10Pharmacyclics Reports Second Quarter 2014 Results 11Pharmacyclics Reports Second Quarter 2014 Results 12Pharmacyclics Reports Second Quarter 2014 Results 13Pharmacyclics Reports Second Quarter 2014 Results 14Pharmacyclics Reports Second Quarter 2014 Results 15Pharmacyclics Reports Second Quarter 2014 Results 16Pharmacyclics Reports Second Quarter 2014 Results 17Pharmacyclics Reports Second Quarter 2014 Results 18Pharmacyclics Reports Second Quarter 2014 Results 19Pharmacyclics Reports Second Quarter 2014 Results 20Pharmacyclics Reports Second Quarter 2014 Results 21Pharmacyclics Reports Second Quarter 2014 Results 22Pharmacyclics Reports Second Quarter 2014 Results 23Pharmacyclics Reports Second Quarter 2014 Results 24Pharmacyclics Reports Second Quarter 2014 Results 25
...   OncoSec Medical Incorporated (OTCBB:ONCS), which is ... therapies to treat solid tumor cancers, today announced ... company,s Phase II Merkel cell carcinoma clinical trial, ... The Journal Newspaper.    (Logo: ...
... AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX ), ("AcelRx"), ... commercialization of innovative therapies for the treatment of acute ... in a Phase 3 study for ARX-01, the Sufentanil ... This first ARX-01 Phase 3 study is a randomized, ...
Cached Medicine Technology:OncoSec's OMS ElectroImmunotherapy Technology Platform and its Ongoing Phase II Merkel Cell Carcinoma Clinical Trial Featured in Seattle Newspaper 2OncoSec's OMS ElectroImmunotherapy Technology Platform and its Ongoing Phase II Merkel Cell Carcinoma Clinical Trial Featured in Seattle Newspaper 3OncoSec's OMS ElectroImmunotherapy Technology Platform and its Ongoing Phase II Merkel Cell Carcinoma Clinical Trial Featured in Seattle Newspaper 4AcelRx Announces Initiation of Phase 3 Clinical Program for ARX-01, the Sufentanil NanoTab® PCA System for the Treatment of Post-Operative Pain 2AcelRx Announces Initiation of Phase 3 Clinical Program for ARX-01, the Sufentanil NanoTab® PCA System for the Treatment of Post-Operative Pain 3AcelRx Announces Initiation of Phase 3 Clinical Program for ARX-01, the Sufentanil NanoTab® PCA System for the Treatment of Post-Operative Pain 4AcelRx Announces Initiation of Phase 3 Clinical Program for ARX-01, the Sufentanil NanoTab® PCA System for the Treatment of Post-Operative Pain 5
(Date:8/1/2014)... in St. Louis helps explain why brain tumors occur ... than similar tumors in females. For example, glioblastomas, the ... often in males, who suffer greater cognitive impairments than ... researchers found that retinoblastoma protein (RB), a protein known ... male brain cells than in female brain cells. , ...
(Date:8/1/2014)... HealthDay Reporter FRIDAY, Aug. 1, 2014 (HealthDay News) ... have significantly less endurance than those who weigh less, a new ... were obese, half were of normal weight -- people who were ... Obesity also was associated with less strength, increased discomfort and ... to 65 years of age -- neither improved nor reduced a ...
(Date:8/1/2014)... -- Almost 140 people die every year in ... States. But there are several simple ways ... prevention coordinator at Cincinnati Children,s Hospital Medical Center,s ... center news release. "As families begin to ... for parents and children to go over school ...
(Date:8/1/2014)... Summer is here, and with it comes the ... and they can be a pain for dogs. Animal Emergency ... their customers get rid of ticks and prevent them completely. ... the summer, which is why they are so active during ... woodland areas and carry a number of diseases, including lyme ...
(Date:8/1/2014)... and transgender individuals who want to conceive a child ... heterosexual and cisgendered peers, such as reduced fertility, but ... legal challenges to become parents. A comprehensive review of ... presented in the article " LGBT Assisted Reproduction: Current ... LGBT Health , a peer-reviewed journal from Mary ...
Breaking Medicine News(10 mins):Health News:Study reveals one reason brain tumors are more common in men 2Health News:Obesity Might Slow You Down at Work 2Health News:Obesity Might Slow You Down at Work 3Health News:Expert Offers School Bus Safety Tips 2Health News:Tis the Season for Tick Prevention 2Health News:Advances in assisted reproduction create more options and new legal issues for LGBT couples 2
... subjects that they were actually losing weight.,// ,Researchers belonging ... believe that they were losing weight when in reality they ... which gave the illusion that their hands were moving inward. ... creating a new body image. , The stimulators used ...
... to new research, elderly heart failure patients in United ... but lose that advantage over time.// ,Their study ... of Internal Medicine. ,Heart failure is the most ... older in both countries. ,The authors compared process ...
... have made the task of hasseled mothers easier by revealing ... foods even when in the womb. Making the task of ... they want their babies to when they are pregnant. ... of amniotic fluid a day and it is believed that ...
... conducted by researchers at University of Texas Southwestern Medical ... problem //faced by diabetics by increasing their blood pressure. ... professor and chief of the division of nutrition and ... a high-carb diet on blood pressure with a diet ...
... that the libido of a patient may be affected ... The secretion and creation of testosterone triggered by some ... of the patient. ,For most epileptics, however, treating ... a sensible approach, experts say. ,If no drugs ...
... to a latest survey, there is a steady decline in ... // . ,The findings were presented at the ... month by researchers from Cancer Research UK and the UK ... while cancer incidence rates have remained stable, there has been ...
Cached Medicine News:Health News:Disparity In Survival Rates In US and Canadian heart Patients 2Health News:Carbohydrate-rich Diet In Diabetes Raises Blood Pressure 2
The Duran Flexible Annuloplasty System encompasses both performance and practicality....
This CLS number is a new product number, created to easily match Cornings product number. If showing no availability yet, please order under the old Sigma-Aldrich number (Z71,407-0) or contact custom...
... Pipette is a synonym for pipetting accuracy, ... design, and superior operating comfort. Its single, ... measuring stroke and blow-out as well as ... ensures utmost accuracy and precision. Ejection sleeve ...
... The new Finnpipette Focus from Thermo Labsystems ... uncompromising performance. Advanced features such as ... fine volume adjustment on microvolumes help to ... single channel pipettes. The new interchangeable handle ...
Medicine Products: